Medicus Pharma Secures $5.1 Million Through Warrant Inducement Agreement

Medicus Pharma Ltd. (NASDAQ:MDCX) announced a warrant inducement agreement, facilitating the immediate exercise of all outstanding Series A and B Warrants. This transaction is expected to generate $5.1 million in gross proceeds. Maxim Group LLC acts as the exclusive financial advisor for the deal.

The company adjusted the exercise price of the Warrants to $1.92, compelling the investor to purchase 2,680,000 common shares. Additionally, Medicus will issue unregistered Series C and D Warrants for 4,020,000 shares at a $2.00 exercise price, expiring in five and a half years.

This agreement demonstrates Medicus's strategic moves within the precision biotech field, focusing on advancing therapeutic developments. Closing is anticipated around December 5, 2025, following standard closing conditions.